High Cholesterol? Clinical Study Opportunity

Heart disease remains the leading cause of death in the United States, and high cholesterol, particularly elevated LDL-C (bad cholesterol), is a significant contributing factor. For Black adults, who face a higher risk of heart disease mortality, understanding and managing cholesterol levels is crucial. If you have high cholesterol, you might be eligible to participate in a new clinical research study sponsored by Merck.

The Importance of Diverse Clinical Trials

Historically, clinical research has often lacked diversity, which can limit our understanding of how treatments affect different populations. Adrelia Allen, Executive Director of Clinical Trial Patient Diversity at Merck, emphasizes the importance of equity in studies. “It’s important to have equity in clinical studies. This means that the people in the studies should represent the people who are most likely to have the health condition and may need the study medicine the most,” she stated.

This study aims to include participants who reflect the diverse population affected by high cholesterol, ensuring that potential new treatments are evaluated for effectiveness and safety across various communities. This commitment to diversity is vital for developing medicines that work for everyone.

Investigational Treatment for High Cholesterol

Researchers are currently investigating an investigational PCSK9 inhibitor, which is designed to help treat high cholesterol. What makes this study particularly noteworthy is that the investigational medicine is being studied as a daily oral pill, offering an alternative to injections. The study is evaluating the safety and efficacy of this new treatment, specifically its potential to lower LDL-C levels and reduce the risk of adverse cardiovascular events like heart attacks and strokes.

Who Qualifies for the Study?

Merck is looking for individuals aged 18 or older who meet specific criteria. You may be eligible if you:

• Currently take a statin medication to lower cholesterol but still need to lower your LDL-C levels.
• Have a high risk of heart attack or stroke and have high cholesterol despite taking a statin for at least one month.
• Have familial hypercholesterolemia (an inherited condition causing high cholesterol) and still have high cholesterol even after taking a statin for at least one month.

If you qualify and decide to join, you will receive the study medication and all study-related medical exams at no cost. Additionally, travel-related expenses, such as bus fare or gas for driving to study site visits, will be reimbursed. Health insurance is not required to participate.

A Call to Participate

Dr. Robert Blaustein, Associate Vice President for Clinical Research at Merck Research Laboratories, encourages eligible individuals to consider participating. “These ongoing clinical studies will help us understand whether our investigational once-daily oral PCSK9 inhibitor will be an effective treatment for certain people with high cholesterol,” he said. “I encourage anyone who meets the eligibility criteria to speak with your health care provider to see if one of the clinical studies may be suitable for you.”

This is a valuable opportunity to contribute to medical research, potentially benefit from a new treatment, and help ensure that future medications are developed with diverse populations in mind. For more information and to see if you might be a candidate, visit coralreefstudies.com.